NCT06100887View on ClinicalTrials.gov

Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Sevasemten Dose 1

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 2

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 3

Sevasemten is administered orally once per day

DRUG

Placebo

Placebo is administered orally once per day

Trial Locations (7)

27278

Rare Disease Research, Hillsborough

32610

University of Florida, Gainesville

43205

Nationwide Children's Hospital, Columbus

63110

Washington University School of Medicine, St Louis

90095

UCLA Medical Center, Los Angeles

95817

UC Davis Medical Center, Sacramento

01605

University of Massachusetts Memorial Medical Center, Worcester

Sponsors
All Listed Sponsors
lead

Edgewise Therapeutics, Inc.

INDUSTRY